SCHEMBL3132202

SCHEMBL3132202

CC(=O)N(C)Cc1ccc(Br)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
POLB P06746 1/20 0.59
MAPT P10636 1/20 0.59
LMNA P02545 2/20 0.54
PYCR1 P32322 4/20 0.50
LSS P48449 2/20 0.48
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
MAOB P27338 1/20 0.46
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1893045 0.86 PYCR1 (0.52) ALDH1A1SMN1; SMN2LMNAPYCR1LSS
SCHEMBL23997228 0.84 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2POLBMAPTLMNA
SCHEMBL13114706 0.82 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2POLBMAPTHDAC3
SCHEMBL171719 0.82 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2POLBMAPTPYCR1
SCHEMBL2760548 0.80 RIPK1 (0.60) ALDH1A1SMN1; SMN2POLBMAPTLMNA
SCHEMBL2238302 0.80 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2POLBMAPTLMNA
SCHEMBL6412640 0.80 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2POLBMAPTLMNA
SCHEMBL24723659 0.80 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2POLBMAPTHDAC3
SCHEMBL31707298 0.80 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2POLBMAPTPYCR1
SCHEMBL14412216 0.80 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2POLBMAPTHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106061480-B Therapeutic inhibitory compounds 莱福斯希医药公司 2020-02-28 CN disclosed
EP-3089746-A1 THERAPEUTIC INHIBITORY COMPOUNDS Lifesci Pharmaceuticals, Inc. (BB) 2016-11-09 EP disclosed
CN-106061480-A Therapeutic inhibitory compounds 莱福斯希医药公司 2016-10-26 CN disclosed
EP-2736886-B1 SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INT (DE) 2016-09-14 EP disclosed
EP-2736886-B1 SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INT (DE) 2016-09-14 EP disclosed
CN-103827090-B Substituted quinolines and their use as pharmaceuticals BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-04-20 CN disclosed
US-9199937-B2 Substituted quinolines and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-12-01 US disclosed
US-9199937-B2 Substituted quinolines and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-12-01 US disclosed
US-9199937-B2 Substituted quinolines and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-12-01 US disclosed
WO-2015103317-A1 THERAPEUTIC INHIBITORY COMPOUNDS LIFESCI PHARMACEUTICALS, INC. (BB) 2015-07-09 WO disclosed
US-7566735-B2 Compounds which potentiate AMPA receptor and uses thereof in medicine GLAXO GROUP LIMITED (GB) 2009-07-28 US disclosed
US-7566735-B2 Compounds which potentiate AMPA receptor and uses thereof in medicine GLAXO GROUP LIMITED (GB) 2009-07-28 US disclosed
CN-101448792-A Compounds that potentiate AMPA receptors and their use in medicine GLAXO GROUP LTD (GB) 2009-06-03 CN disclosed
US-20090118280-A1 Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine HARRISON STEPHEN 2009-05-07 US disclosed
US-20090118280-A1 Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine HARRISON STEPHEN 2009-05-07 US disclosed
US-20090118280-A1 Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine HARRISON STEPHEN 2009-05-07 US disclosed
US-20080045532-A1 Compounds which potentiate AMPA receptor and uses thereof in medicine GLAXO GROUP LIMITED (GB) 2008-02-21 US disclosed
US-20080045532-A1 Compounds which potentiate AMPA receptor and uses thereof in medicine GLAXO GROUP LIMITED (GB) 2008-02-21 US disclosed
US-20080045532-A1 Compounds which potentiate AMPA receptor and uses thereof in medicine GLAXO GROUP LIMITED (GB) 2008-02-21 US disclosed
WO-2007107539-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118280-A1 Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine GRIN1, GRM2, GRM1 ALDH1A1 1395/4885SMN1; SMN2 3074/4885POLB 3092/4885
US-20080045532-A1 Compounds which potentiate AMPA receptor and uses thereof in medicine GRIN1, GRM2, GRM1 ALDH1A1 1395/4885SMN1; SMN2 3074/4885POLB 3092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.